Every engagement is scoped to the decision at hand — from strategy definition through vendor selection, deployment and education.
Hospitals, diagnostic groups, pathology laboratories.
Health systems and diagnostic organizations need a defensible AI adoption strategy — not a list of tools.
Pathology labs, university hospitals, diagnostic networks.
Pathology transformation involves scanners, IMS, LIS, AI vendors and workflow redesign — each with strong opinions.
Providers, investors, pharma and biotech.
AI vendor claims are hard to compare and harder to validate against real clinical performance.
AI startups, CE/FDA-stage companies, large technology vendors.
AI and digital pathology vendors need to understand the healthcare buyer, workflow and commercial reality.
Executives, clinicians, boards and investment teams.
Clinical, operational and executive teams need shared literacy to make AI decisions confidently.